Product Code: GVR-1-68038-226-6
Bone Morphogenetic Protein Market Growth & Trends:
The global bone morphogenetic protein market size is expected to reach USD 459.9 million by 2030, registering a CAGR of 4.93% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing incidence of spinal fusion, trauma, and small bone surgeries coupled with demand for faster bone recovery are the key drivers affirming growth of BMP market.
Low back pain and spinal disc dislocation are some of the most common occupational hazards. Over 75% of such disorders require spinal surgery after noninvasive treatment options are unable to provide any relief. Minimally invasive surgery, shorter hospital stays, and fast recovery are common demands observed among patients. BMP has gained high acceptance among orthopedic surgeons in recent years owing to its ability to cater above mentioned benefits
Sport-related injuries, growing geriatric population, and increasing awareness about osteoinduction products as an alternative to bone grafting are other drivers accentuating market growth. BMP has reported outstanding results over bone graft, such as lack of donor morbidity, extensive surgical procedure, higher recovery time, pain & numbness, and high cost.
Bone Morphogenetic Protein Market Report Highlights:
- rhBMP-2 and rhBMP-7 are the commercially available recombinant BMPs. rhBMP-2 is widely known for its high osteoinductive property for faster formation of bone and cartilage in bone fusion procedures.
- The rhBMP-2 segment held the largest market share of 73.9% in 2024 and is anticipated to grow at the higher CAGR from 2025 to 2030.
- rhBMP-7 segment is expected to grow at a moderate CAGR from 2025 to 2030. As healthcare professionals increasingly look for alternatives to autografts for bone repair, rhBMP-7's ability to promote healing without the complications associated with harvesting grafts could drive its adoption in clinical practice.
- The spinal fusion segment held the largest market share of 50.3% in 2024. The growth is attributed to the development of effective and efficient solutions, the increasing acceptance of these proteins over conventional treatments, and the ongoing research initiatives that strengthen their position in the market.
- North America held the largest market share of 49.6% in the global bone morphogenetic protein market in 2024. High number of orthopedic surgical procedures, and availability of favorable reimbursement policies are drivers that can be attributed to for largest share.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.2.1. Type Segment
- 1.2.2. Application Segment
- 1.3. Information analysis
- 1.4. Market formulation & data visualization
- 1.5. Data validation & publishing
- 1.6. Information Procurement
- 1.7. Information or Data Analysis
- 1.8. Market Formulation & Validation
- 1.9. Market Model
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Growing demand for minimally invasive medical procedures
- 3.2.1.2. Increasing incidence of sports-related injuries
- 3.2.1.3. Increasing target population
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. Complications associated with the use of Bone Morphogenic Proteins
- 3.2.2.2. Availability of alternative treatments
- 3.3. Industry Analysis Tools
- 3.3.1. Porter's Five Forces Analysis
- 3.3.2. PESTEL Analysis
- 3.3.3. COVID-19 Impact Analysis
Chapter 4. Bone Morphogenetic Protein Market: Type Business Analysis
- 4.1. Type Segment Dashboard
- 4.2. Global Bone Morphogenetic Protein Market Type Movement Analysis
- 4.3. Global Bone Morphogenetic Protein Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
- 4.4. rhBMP-2
- 4.4.1. Global rhBMP-2 Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.5. rhBMP-7
- 4.5.1. Global rhBMP-7 Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Bone Morphogenetic Protein Market: Application Business Analysis
- 5.1. Application Segment Dashboard
- 5.2. Global Bone Morphogenetic Protein Market Application Movement Analysis
- 5.3. Global Bone Morphogenetic Protein Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
- 5.4. Spinal Fusion
- 5.4.1. Global Spinal Fusion Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.5. Trauma
- 5.5.1. Global TraumaMarket Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.6. Reconstruction
- 5.6.1. Global Reconstruction Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.7. Oral Maxillofacial
- 5.7.1. Global Oral Maxillofacial Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Bone Morphogenetic Protein Market: Regional Estimates & Trend Analysis by Type and Application
- 6.1. Regional Dashboard
- 6.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
- 6.3. North America
- 6.3.1. North America Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.3.2. U.S.
- 6.3.2.1. Key Country Dynamics
- 6.3.2.2. Market and Competitive Scenario
- 6.3.2.3. U.S. Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.3.3. Canada
- 6.3.3.1. Key Country Dynamics
- 6.3.3.2. Market and Competitive Scenario
- 6.3.3.3. Canada Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.3.4. Mexico
- 6.3.4.1. Key Country Dynamics
- 6.3.4.2. Market and Competitive Scenario
- 6.3.4.3. Mexico Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4. Europe
- 6.4.1. Europe Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4.2. UK
- 6.4.2.1. Key Country Dynamics
- 6.4.2.2. Market and Competitive Scenario
- 6.4.2.3. UK Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4.3. Germany
- 6.4.3.1. Key Country Dynamics
- 6.4.3.2. Market and Competitive Scenario
- 6.4.3.3. Germany Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4.4. France
- 6.4.4.1. Key Country Dynamics
- 6.4.4.2. Market and Competitive Scenario
- 6.4.4.3. France Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4.5. Italy
- 6.4.5.1. Key Country Dynamics
- 6.4.5.2. Market and Competitive Scenario
- 6.4.5.3. Italy Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4.6. Spain
- 6.4.6.1. Key Country Dynamics
- 6.4.6.2. Market and Competitive Scenario
- 6.4.6.3. Spain Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4.7. Denmark
- 6.4.7.1. Key Country Dynamics
- 6.4.7.2. Market and Competitive Scenario
- 6.4.7.3. Denmark Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4.8. Sweden
- 6.4.8.1. Key Country Dynamics
- 6.4.8.2. Market and Competitive Scenario
- 6.4.8.3. Sweden Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4.9. Norway
- 6.4.9.1. Key Country Dynamics
- 6.4.9.2. Market and Competitive Scenario
- 6.4.9.3. Norway Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5. Asia Pacific
- 6.5.1. Asia Pacific Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5.2. Japan
- 6.5.2.1. Key Country Dynamics
- 6.5.2.2. Market and Competitive Scenario
- 6.5.2.3. Japan Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5.3. China
- 6.5.3.1. Key Country Dynamics
- 6.5.3.2. Market and Competitive Scenario
- 6.5.3.3. China Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5.4. India
- 6.5.4.1. Key Country Dynamics
- 6.5.4.2. Market and Competitive Scenario
- 6.5.4.3. India Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5.5. Australia
- 6.5.5.1. Key Country Dynamics
- 6.5.5.2. Market and Competitive Scenario
- 6.5.5.3. Australia Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5.6. Thailand
- 6.5.6.1. Key Country Dynamics
- 6.5.6.2. Market and Competitive Scenario
- 6.5.6.3. Thailand Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5.7. South Korea
- 6.5.7.1. Key Country Dynamics
- 6.5.7.2. Market and Competitive Scenario
- 6.5.7.3. South Korea Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.6. Latin America
- 6.6.1. Latin America Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.6.2. Brazil
- 6.6.2.1. Key Country Dynamics
- 6.6.2.2. Market and Competitive Scenario
- 6.6.2.3. Brazil Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.6.3. Argentina
- 6.6.3.1. Key Country Dynamics
- 6.6.3.2. Market and Competitive Scenario
- 6.6.3.3. Argentina Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.7. MEA
- 6.7.1. MEA Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.7.2. South Africa
- 6.7.2.1. Key Country Dynamics
- 6.7.2.2. Market and Competitive Scenario
- 6.7.2.3. South Africa Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.7.3. Saudi Arabia
- 6.7.3.1. Key Country Dynamics
- 6.7.3.2. Market and Competitive Scenario
- 6.7.3.3. Saudi Arabia Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.7.4. UAE
- 6.7.4.1. Key Country Dynamics
- 6.7.4.2. Market and Competitive Scenario
- 6.7.4.3. UAE Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.7.5. Kuwait
- 6.7.5.1. Key Country Dynamics
- 6.7.5.2. Market and Competitive Scenario
- 6.7.5.3. Kuwait Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Competitive Landscape
- 7.1. Participant Categorization
- 7.2. Strategy Mapping
- 7.3. Company Market Position Analysis, 2024
- 7.4. Participant's Overview
- 7.4.1. Medtronic plc
- 7.4.1.1. Overview
- 7.4.1.2. Financial Performance
- 7.4.1.3. Product Benchmarking
- 7.4.1.4. Strategic Initiatives
- 7.4.2. Cellumed Co., Ltd.
- 7.4.2.1. Overview
- 7.4.2.2. Financial Performance
- 7.4.2.3. Product Benchmarking
- 7.4.2.4. Strategic Initiatives
- 7.4.3. Cell Guidance Systems LLC
- 7.4.3.1. Overview
- 7.4.3.2. Financial Performance
- 7.4.3.3. Product Benchmarking
- 7.4.3.4. Strategic Initiatives
- 7.4.4. Merck KGaA
- 7.4.4.1. Overview
- 7.4.4.2. Financial Performance
- 7.4.4.3. Product Benchmarking
- 7.4.4.4. Strategic Initiatives
- 7.4.5. Prospec-Tany Technogene Ltd.
- 7.4.5.1. Overview
- 7.4.5.2. Financial Performance
- 7.4.5.3. Product Benchmarking
- 7.4.5.4. Strategic Initiatives
- 7.4.6. Qkine Ltd.
- 7.4.6.1. Overview
- 7.4.6.2. Financial Performance
- 7.4.6.3. Product Benchmarking
- 7.4.6.4. Strategic Initiatives
- 7.4.7. Bio-Techne.
- 7.4.7.1. Overview
- 7.4.7.2. Financial Performance
- 7.4.7.3. Product Benchmarking
- 7.4.7.4. Strategic Initiatives
- 7.4.8. Thermo Fisher Scientific Inc.
- 7.4.8.1. Overview
- 7.4.8.2. Financial Performance
- 7.4.8.3. Product Benchmarking
- 7.4.8.4. Strategic Initiatives
- 7.4.9. Proteintech Group, Inc.
- 7.4.9.1. Overview
- 7.4.9.2. Financial Performance
- 7.4.9.3. Product Benchmarking
- 7.4.9.4. Strategic Initiatives
- 7.4.10. STEMCELL Technologies
- 7.4.10.1. Overview
- 7.4.10.2. Financial Performance
- 7.4.10.3. Product Benchmarking
- 7.4.10.4. Strategic Initiatives
- 7.4.11. Sartorius Stedim Biotech
- 7.4.11.1. Overview
- 7.4.11.2. Financial Performance
- 7.4.11.3. Product Benchmarking
- 7.4.11.4. Strategic Initiatives